Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04199728 · ClinicalTrials.gov registry record · Phase 1
Use of a GLP-1R Agonist to Treat Opioid Use Disorder
A Phase 1 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT04199728 is a Phase 1 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 27 participants.
The verdict
NCT04199728, a Phase 1 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This research is being done to find out if liraglutide (brand name is Saxenda®) can safely and effectively reduce craving for opioids in patients with opioid use disorder, a primary factor contributing to early relapse.
Interventions
- DRUG Placebo
- DRUG Liraglutide Pen Injector
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-10-18 |
| Est. Completion | 2023-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04199728
The ClinicalTrials.gov registry entry for NCT04199728 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04199728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04199728 about?
NCT04199728 is a clinical study titled "Use of a GLP-1R Agonist to Treat Opioid Use Disorder". This research is being done to find out if liraglutide (brand name is Saxenda®) can safely and effectively reduce craving for opioids in patients with opioid use disorder, a primary factor contributing to early relapse.
What is the current status of trial NCT04199728?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2021-10-18. Estimated completion is 2023-09-13.
What interventions are being tested in trial NCT04199728?
The interventions under investigation include: Placebo (DRUG), Liraglutide Pen Injector (DRUG).
Who is sponsoring clinical trial NCT04199728?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.